enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. ‘A huge shock to the system’: Doctors warn about asthma ...

    www.aol.com/huge-shock-system-doctors-warn...

    GSK did price the authorized generic lower than branded Flovent; one package of Flovent HFA in the 110 microgram dose, for example, costs $273.83, about 50% more than the $177.99 wholesale ...

  3. Popular asthma inhaler will be discontinued Jan. 1. Here’s ...

    www.aol.com/news/popular-asthma-inhaler...

    The discontinuation aligns with a change to Medicaid rebates that may have had the inhaler’s manufacturer selling the drug at a loss. Popular asthma inhaler will be discontinued Jan. 1. Here’s ...

  4. List of withdrawn drugs - Wikipedia

    en.wikipedia.org/wiki/List_of_withdrawn_drugs

    [1] Alatrofloxacin: 2006 Worldwide Serious hepatotoxicity leading to liver transplant or death. [2] Alclofenac: 1979 UK Vasculitis [3] Alpidem (Ananxyl) 1995 Worldwide Not approved in the US, withdrawn in France in 1994 [4] and the rest of the market in 1995 because of rare but serious hepatotoxicity. [3] [5] Alosetron (Lotronex) 2000 US

  5. Fluticasone - Wikipedia

    en.wikipedia.org/wiki/Fluticasone

    Fluticasone is a manufactured glucocorticoid used to treat nasal congestion. [1] [2] [3] [4] [5] Both the esters, fluticasone propionate (sold as Flovent) and ...

  6. Since then, GSK has conducted additional pre-clinical research and, after assessing various options, has elected to discontinue further development of GSK2251052 and return all rights to ...

  7. Fluticasone furoate/vilanterol - Wikipedia

    en.wikipedia.org/wiki/Fluticasone_furoate/vilanterol

    In 2013, the drug was approved for use in the United States by the Food and Drug Administration (FDA) for long-term maintenance treatment of airflow obstruction in people with COPD, including chronic bronchitis and emphysema, [6] and the European Medicines Agency approved it as a second-line therapy for the treatment of COPD and asthma. [7]

  8. GSK1016790A - Wikipedia

    en.wikipedia.org/wiki/GSK1016790A

    GSK1016790A (aka GSK101) is a drug developed by GlaxoSmithKline which acts as a potent and selective agonist for the TRPV4 receptor. It has been used to study the role of TRPV4 receptors in the function of smooth muscle tissue, particularly that lining blood vessels, lymphatic system , and the bladder .

  9. GSK's asthma drug Nucala meets main goal in study on ... - AOL

    www.aol.com/news/gsks-asthma-drug-nucala-meets...

    (Reuters) -British drugmaker GSK said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive pulmonary disease (COPD), or ...